Iovance Biotherapeutics Inc at Barclays Global Healthcare Conference Transcript
Hello, everyone. My name is Etzer Darout, the senior biotech analyst at Barclays. It's my pleasure to have Iovance Therapeutics for our next fireside chat. With me, today, I have Brian Gastman, Executive Vice President of Transitional Medicine and Research; and Sara Pellegrino, Head of IR.
Thank you so much for joining us this morning. Maybe just Brian, just Sara, just maybe give us an overview of Iovance for those less familiar with the story.
Great. So that's a great place to start. At Iovance, we have three key pillars of strength that we are focusing on in 2026 and into the future. Our first pillar of strength is our US commercial business driven by our commercial product Amtagvi, which is approved in previously treated advanced melanoma in the United States and has at least a $1 billion US peak sales potential.
The next pillar of strength is our pipeline, which we are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
